Follistatin 344

Follistatin 344 – Benefits & Side Effects

Follistatin 344 – Protocol

Follistatin 344 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Follistatin 344 – Identification

Common Names: Follistatin 344, Follistatin-344, FS-344, FS344, FST-344, Follistatin isoform 344, Activin-Binding Protein, FSH-Suppressing Protein

CAS Number: 80449-31-6 (primary); 100043-71-8 (alternate); 129954-34-3 (supplier variants)

Molecular Formula: Varies by source: C₁₃₅₀H₂₁₅₃N₄₀₅O₄₃₃S₃₉ (some suppliers); C₈₅₂H₁₃₄₇N₂₂₉O₂₅₅S₆ (others); C₂₀₃H₃₁₇N₅₅O₆₄S₁ (alternate)

Molecular Weight: Approximately 37-40 kDa (typically ~39 kDa for glycosylated recombinant form); 3780 g/mol reported by some suppliers for alternative calculations

Origin & Type Classification:

• Source: Natural; generated through alternative splicing of FST gene; recombinant forms produced in HEK293 cells or other expression systems

• Biosynthesis: Ribosomal; produced from mRNA transcripts generated by alternative splicing; recombinant forms engineered in mammalian cells

• Functional Class: Glycoprotein; TGF-β superfamily inhibitor; myostatin antagonist; activin-binding protein; growth factor regulator

Additional Information:

• Amino Acid Sequence: 344 amino acid precursor protein (full-length); mature FS315 sequence 315 amino acids after signal peptide removal; contains the distinctive 27-amino acid acidic C-terminal tail (unique to FS344-derived FS315 isoform)

• Sequence Length: 344 amino acids (preprotein including signal sequence); 315 amino acids mature FS315 after signal peptide cleavage

• Structural Type: Monomeric glycoprotein; contains multiple disulfide bonds; heavily post-translationally glycosylated

• Post-translational Modifications: N-linked and O-linked glycosylation; proteolytic cleavage of signal peptide generates FS315; further C-terminal cleavage may generate FS303 intermediate

• Salt Form: Available as lyophilized powder requiring reconstitution in bacteriostatic water; can be provided in phosphate-buffered saline

• Key Structural Features: The C-terminal 27-amino acid acidic extension (44% acidic residues) masks heparan sulfate-binding sites, creating FS315 as a circulating/systemic isoform; contains ~36 cysteines forming disulfide bonds characteristic of multidomain extracellular proteins

• Known Synonyms: FS-344, FST-344, Follistatin isoform 344, Activin inhibitor

• Supplier Identification Variations: Recombinant human follistatin 344 commonly expressed in HEK293 mammalian cells with or without His-tag; UniProt ID P19883 for human FST gene product encompasses all isoforms

Database Links:

• PubChem: CID 178101631 (follistatin protein); CID 5281027 (generic follistatin entry)

• UniProt: P19883 (human FST gene product; encompasses FS288, FS303, FS315, FS344 isoforms from alternative splicing and proteolytic processing)

• PDB: 2P6A (FS315-Activin A complex); multiple other structure entries for follistatin domains

• NCBI: Gene ID 10468 (human FST gene); extensive literature available through PubMed

Important Note: FS344 exists predominantly as FS315 after signal peptide cleavage. The distinction between FS344 and FS315 is the presence of the signal peptide in the precursor (FS344) versus its absence in the mature circulating form (FS315). The FS344-derived FS315 isoform is the systemic/circulating form, whereas FS288 (derived from FS317 alternatively-spliced transcript) is the tissue-associated, heparin-binding form.

Follistatin 344 – Research

Study: Long-Term Enhancement of Skeletal Muscle Mass and Strength by Follistatin-344
Benefits: Provides long-lasting muscle growth (over 2 years), safe for the heart, and avoids reproductive side effects.
Link: https://www.pnas.org/doi/10.1073/pnas.0709144105
Summary: Follistatin 344 (FS-344) is actually the "blueprint" version used in gene therapy. When injected, the body reads this blueprint and turns it into the circulating protein (FS-315). In a major study on monkeys, a single treatment with FS-344 led to muscle growth that lasted for over 15 months! The animals got stronger and bigger without any negative effects on their heart or ability to have babies (which was a risk with other versions). This study is famous because it showed that FS-344 is the safest, most reliable way to produce sustained muscle growth for treating diseases like muscular dystrophy. It’s like installing a permanent software update that tells your muscles to keep growing.

Study: Follistatin Gene Therapy for Sporadic Inclusion Body Myositis
Benefits: Improves walking distance in patients with muscle disease, safe for human use, prevents muscle wasting.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC5383643/
Summary: This was a groundbreaking human trial. Six patients with a muscle-wasting disease (IBM) received injections of Follistatin 344 gene therapy into their leg muscles. The goal was to stop their legs from getting weaker. The results showed that the treatment was safe and effectively improved the distance they could walk in a 6-minute test. Some patients even saw their muscle strength stabilize instead of getting worse. This proves that the science seen in mice translates to real people. By using FS-344, the doctors could target specific muscles (like the quads) to save them from wasting away, offering hope for conditions that currently have no cure.

Study: Increasing Lean Muscle Mass via Nanoparticle-Mediated Delivery of FS-344 mRNA
Benefits: Burns fat while building muscle, reduces "bad" fat tissue, and works without using viruses.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC6276093/
Summary: Most gene therapies use a virus to deliver the message, which can be scary. This study used "nanoparticles" (tiny fat bubbles) to deliver the FS-344 message instead. It worked perfectly: the liver read the message and pumped out Follistatin for 3 days. The result? The mice built muscle and, surprisingly, lost a significant amount of body fat. The Follistatin blocked myostatin (which stops muscle) and activin A (which promotes fat). This dual-action of "more muscle, less fat" makes FS-344 a prime candidate not just for disease, but for combating obesity and frailty in older adults.

Follistatin 344 – Research Links